Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (20499)	5/11/1998 7:40:00 PM
From: Andrew H	Read Replies (4) \| Respond to of 32384

I agree with your analysis of the situation.

To: Russian Bear who wrote (20499)	5/11/1998 8:45:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

RB,What I find funny is that SRGN looks to me like LGND in miniature. Lots of targets and not enough money to develop them. SRGN has 6 target molecules where each molecule might have multiple indications. Another thing I find funny is LGND is spending 30+million to be profitable in 99. So they think cash and dilution will be less than revenue obviously. They might want it for the other indications, but it is CTCL that they expect to generate the revs. Unless they license the other indications out I guess. squetch